J&J Quits RSV Development With Two Rivals Already Poised For US Approval

 
• By Joseph Haas

The pharma, which has been de-emphasizing vaccines and infectious disease of late, will end its Phase III trial for an RSV vaccine with May approvals pending for both Pfizer’s and GSK’s candidates.

Janssen Pharmaceutica sign and logo
J&J steps away from RSV vaccine development • Source: Michael Vi / Shutterstock.com

More from Strategy

More from Business